title: Alternative treatment methods attenuate the development of NAFLD: A review of resveratrol molecular mechanisms and clinical trials.
abstract: Nonalcoholic fatty liver disease (NAFLD) is considered to be one of the most common liver pathologies that occur widely among societies with a predominance of the Western dietary pattern. NAFLD may progress from hepatic steatosis to nonalcoholic steatohepatitis (NASH), subsequently leading to cirrhosis and becoming a major cause of hepatocellular carcinoma. Thus its prevention and therapy play an important role in hepatology. To our knowledge, there is no effective treatment for patients with NAFLD. The aim of this review was to summarize the results of recent alternative treatment studies conducted both on cell cultures and in vivo that concern molecular effects of resveratrol (3,5,4'-trihydroxystilbene) in the treatment of NAFLD. The precise metabolism, pharmacology, and clinical trials with different concentrations of resveratrol were described. The review also presents a brief summary of other alternative treatment methods of NAFLD and their mechanisms compared with current clinical understanding.
authors.affiliation: Department of Physiology, Medical University of Bialystok, Bialystok, Poland.
authors.forename: Tomasz
authors.initials: T
authors.lastname: Charytoniuk
authors.affiliation: Department of Physiology, Medical University of Bialystok, Bialystok, Poland. Electronic address: drygalskikrzysztof@gmail.com.
authors.forename: Krzysztof
authors.initials: K
authors.lastname: Drygalski
authors.affiliation: Department of Physiology, Medical University of Bialystok, Bialystok, Poland.
authors.forename: Karolina
authors.initials: K
authors.lastname: Konstantynowicz-Nowicka
authors.affiliation: Department of Physiology, Medical University of Bialystok, Bialystok, Poland.
authors.forename: Klaudia
authors.initials: K
authors.lastname: Berk
authors.affiliation: Department of Physiology, Medical University of Bialystok, Bialystok, Poland.
authors.forename: Adrian
authors.initials: A
authors.lastname: Chabowski
mesh_terms: D000529:Complementary Therapies / Q000379:methods; D022781:Hepatocytes / Q000187:drug effects; D006801:Humans; D007333:Insulin Resistance; D050356:Lipid Metabolism / Q000187:drug effects; D008099:Liver / Q000187:drug effects / Q000378:metabolism; D065626:Non-alcoholic Fatty Liver Disease / Q000188:drug therapy*; D016032:Randomized Controlled Trials as Topic; D000077185:Resveratrol; D013267:Stilbenes / Q000494:pharmacology*
chemical_list: D013267:Stilbenes; D000077185:Resveratrol
keywords: Alternative NAFLD treatment; Clinical trials; Liver steatosis; Metabolism of resveratrol; NAFLD; Resveratrol